Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab나탈리주맙으로 치료받은 다발성 경화증 환자에서 BNT162b2 mRNA COVID-19 백신에 대한 6개월 체액 반응Article Published on 2022-05-012022-09-11 Journal: Neurological Sciences [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] A significant reduction age All participants BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine booster dose booster doses both group both groups clinician collected comparable COVID-19 COVID-19 vaccination COVID-19 vaccine Cutoff develop DiaSorin first dose healthy humoral humoral immune response Humoral response IgG IgG antibodies IgG antibody immune response investigated LIAISON limit maintain mRNA mRNA vaccine Multiple multiple sclerosis Natalizumab of BNT162b2 Participants Patient positive positive IgG antibodies SARS-CoV-2 SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 spike protein SARS-CoV-2 vaccine serum sample serum samples Spike protein treated Vaccine [DOI] 10.1007/s10072-022-05940-0 PMC 바로가기 [Article Type] Article
Prospective Pilot Study Evaluating SARS-CoV-2 Transmission-Limiting Measures in an On-Site School현장 학교에서 SARS-CoV-2 전파 제한 조치를 평가하는 예비 파일럿 연구Article Published on 2022-05-012022-09-11 Journal: Academic pediatrics [Category] COVID19(2023년), SARS, 치료기술, [키워드] adhere All participants Asymptomatic asymptomatic infection asymptomatic infections children collected conducted COVID-19 COVID-19 transmission enrolled epidemiological evaluate Evaluating feasibility independent limit Mask measure Mitigation strategies occurred on-site learning participant Participants physical distancing positive preventive measure preventive measures progressed Prospective prospective cohort study Prospective Study reliability reported symptom Research RT-PCR RT-PCR testing SARS-CoV-2 SARS-CoV-2 transmission School school reopening. Schools secondary transmission study period surveillance testing Symptom tested Transmission waned [DOI] 10.1016/j.acap.2021.11.019 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach해외 귀국자를 위한 SARS-CoV-2 스크리닝 전략: 신속한 항원 검사 접근 방식 평가Article Published on 2022-05-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] All participants Analysis Antigen antigen test approach Cell culture Compliance country evaluated Follow-up in vitro include initial International mandatory measure participant PCR positive Potential quarantine Regulation reported resulting risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 testing screening strategy sensitivity Sensitivity and specificity specificity symptom onset tested Travel Travel regulations. viral variant was determined [DOI] 10.1016/j.ijid.2022.02.045 PMC 바로가기 [Article Type] Article
The role and diagnostic accuracy of serology for COVID-19COVID-19에 대한 혈청학의 역할 및 진단 정확도Article Published on 2022-04-192022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] (Abbott) Abbot Abbott Abbott Diagnostics Abbott SARS-CoV-2 IgG Accuracy Adult patient Adult patients All participant All participants anti-S antibody Antibody test best CLIA comparable controls COVID-19 COVID-19 case COVID-19 cases Diagnosis diagnosis of COVID-19 diagnostic Diagnostic accuracy diagnostic test diagnostic tests duration of illness ELISA ELISA kit enrolled evaluate febrile illness Fever followed by Healthcare Diagnostics healthy hospital IgG IgG ELISA IgM Inc. Italy laboratory-confirmed less LIAISON Negative predictive value NPV participant Patient platform Positive predictive value positive predictive values PPV predictive values Protein Roche Roche Diagnostics RT-PCR S1/S2 SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 RT-PCR Seattle sensitivities sensitivity serological Serological assay serological assays serological test Serological tests serology Seven Siemen Siemens south India Specificities specificity Switzerland Symptoms Tarrytown tested Total total antibodies total antibody USA [DOI] 10.1186/s12879-022-07361-y PMC 바로가기 [Article Type] Article
Using information and communication technologies (ICTs) to solve the repressed demand for primary dental care in the Brazilian Unified Health System due to the COVID-19 pandemic: a randomized controlled study protocol nested with a before-and-after study including economic analysis정보 통신 기술(ICT)을 사용하여 COVID-19 전염병으로 인해 브라질 통합 의료 시스템에서 1차 치과 진료에 대한 억압된 수요 해결: 경제 분석을 포함한 전후 연구와 중첩된 무작위 통제 연구 프로토콜Article Published on 2022-04-072022-09-11 Journal: BMC Oral Health [Category] 임상, [키워드] All participant All participants alternative analyses Analysis benefit Care carried Child children clinical trial communication Coronavirus infections COVID-19 COVID-19 pandemic Dental unit develop Effect Effects enrolled feasible health system information Intervention national health system pandemic Perspective platform positive Potential potential benefits primary care Primary outcome Primary outcomes protocol randomization Randomized randomized controlled study RCT receive Registered repressed Research SUS System Teledentistry Telemonitoring Teleorientation. Trial trials [DOI] 10.1186/s12903-022-02101-9 PMC 바로가기 [Article Type] Article
CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 testCHARM: qPCR SARS-CoV-2 테스트 양성 후 무증상 및 증상 감염에 대한 항원 특이적 인터페론-감마 및 IL2 반응의 해병을 위한 COVID-19 건강 조치 대응Article Published on 2022-04-072022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] Action All participants Asymptomatic Asymptomatic cases Cell mediated immunity class correlated COVID-19 COVID-19 symptoms COVID-19 vaccine COVID-19 vaccines dropped enrolled Enrollment epitope Epitopes Follow-up frequencies Frequency IFN-γ IFN-γ response IFN-γ responses IL2 immune response include Infection membrane N and M N and S proteins N protein nucleocapsid occurred participant Participants peaked peptide peptide pool peptides positive Post-infection predicted Protein Proteins qPCR qPCR test Responder response responses S proteins S, N and M proteins SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 test significantly Study participants subjects Support symptomatic symptomatic and asymptomatic symptomatic infection symptomatic participants T cell T cell response T cell responses tested the N protein These data were measured with COVID-19 [DOI] 10.1371/journal.pone.0266691 PMC 바로가기 [Article Type] Article
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trialRIO 시험: 최근 HIV 감염 연구 프로토콜 진단을 받은 참가자를 대상으로 항레트로바이러스 요법과 이중 지속성 HIV 특이적 광범위 중화 항체(bNAb)에 대한 무작위 위약 대조 시험에서 지역사회 참여의 근거, 설계 및 역할 2단계 무작위 2상 시험Article Published on 2022-04-052022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료기술, 치료제, [키워드] 1:1 adverse events All participants Antiretroviral therapy approval Arm ART binding site Blood broadly neutralising antibodies CD4 clinical collaboration Community Complete Concentration concentrations COVID-19 criteria detectable diagnosed DNA double-blinded dual eligible participant Ethics EudraCT exploratory endpoint followed by Frequency HIV HIV infection HIV-negative Hypothesis immunological improvement include individual induce Infection interruption Intervention involved life Measures MHRA neutralising Neutralising Antibodies neutralising antibody onward transmission Open-label outcome participant Placebo placebo-controlled placebo-controlled trial primary endpoint Primary infection protocol Quality of life randomised rationale receive reducing Registered researcher risk secondary serum Stage stage 2 stages survival sustained T cell T cell immunity therapy Trial undetectable Viraemia Viral viral control viral sequence viral sequences Virological remission. was determined with HIV [DOI] 10.1186/s13063-022-06151-w PMC 바로가기 [Article Type] Article
Identification of Natural SARS-CoV-2 Infection in Seroprevalence Studies Among Vaccinated Populations백신 접종 집단 사이의 혈청유병성 연구에서 자연적인 SARS-CoV-2 감염의 확인Article Published on 2022-04-012022-09-11 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] 95% CI Accuracy age All participants an area antibody Antibody assays Antibody testing Area Blood can not capillary capillary blood Cohort composed conducted determine determined by elevated enrolled enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay female Health care Health care worker health care workers identification IgG IgG antibodies IgG antibody IgGs individual individuals Infection MOST natural natural infection nucleocapsid nucleocapsid protein participant Participants performed Population predicted Protein reactive reactivity reported SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 nucleocapsid separated Seroprevalence significantly specificity Spike protein Spike proteins statistically vaccinated individuals vaccination Vaccination Status was determined was tested were assessed [DOI] 10.1016/j.mayocp.2022.02.002 PMC 바로가기 [Article Type] Article
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients항CD20 치료 다발성 경화증 환자에서 1차부터 3차까지의 SARS-CoV-2 mRNA 백신 접종에서 체액성 면역 반응이 지속적으로 감소하고 세포 면역 반응이 지속됨Article Published on 2022-04-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, [키워드] Abbott Abbott Laboratories administration All participant All participants allowance anti-CD20 anti-CD20 therapy Antibody Response B cell BNT162b2 BNT162b2 mRNA Booster vaccine CD20 CD4 CD8 Cellular immune response cellular response Cohort dropped frequencies Frequency humoral include longitudinal study median monoclonal antibodies mRNA vaccination mRNA vaccine Multiple multiple sclerosis no difference Ocrelizumab participant Patient PBMC peptide peptide pool Prophylactic reactive reduced reduction SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG II Quant assay SARS-CoV-2 vaccination second vaccination seropositive Seropositivity Spike-specific T-cell responses Study design sustained T-cell T-cell Response T-cell responses T-cells T-lymphocyte treated vaccination was done were assessed were measured [DOI] 10.1016/j.msard.2022.103729 PMC 바로가기 [Article Type] Article